Engineered Polymer-siRNA Polyplexes Provide Effective Treatment of Lung Inflammation.

Uncontrolled inflammation is responsible for acute and chronic diseases in the lung. Regulating expression of pro-inflammatory genes in pulmonary tissue using small interfering RNA (siRNA) is a promising approach to combatting respiratory diseases. However, siRNA therapeutics are generally hindered at the cellular level by endosomal entrapment of delivered cargo and at the organismal level by inefficient localization in pulmonary tissue. Here we report efficient anti-inflammatory activity in vitro and in vivo using polyplexes of siRNA and an engineered cationic polymer (PONI-Guan). PONI-Guan/siRNA polyplexes efficiently deliver siRNA cargo to the cytosol for highly efficient gene knockdown. Significantly, these polyplexes exhibit inherent targeting to inflamed lung tissue following intravenous administration in vivo. This strategy achieved effective (>70%) knockdown of gene expression in vitro and efficient (>80%) silencing of TNF-α expression in lipopolysaccharide (LPS)-challenged mice using a low (0.28 mg/kg) siRNA dosage.

[1]  V. Rotello,et al.  Cytosolic Protein Delivery Using Modular Biotin-Streptavidin Assembly of Nanocomposites. , 2022, ACS nano.

[2]  Y. Lim,et al.  Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Ramezan Jafari,et al.  Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management , 2021, Pneumonia.

[4]  R. Langer,et al.  Nucleic Acid Delivery for Therapeutic Applications. , 2021, Advanced drug delivery reviews.

[5]  V. Rotello,et al.  Supramolecular Arrangement of Protein in Nanoparticle Structures Predicts Nanoparticle Tropism for Neutrophils in Acute Lung Inflammation , 2021, Nature Nanotechnology.

[6]  S. Sinha,et al.  Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections , 2021, Applied Microbiology and Biotechnology.

[7]  Wei He,et al.  Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome , 2021, Acta Pharmaceutica Sinica B.

[8]  V. Rotello,et al.  Protein Delivery: If Your GFP (or Other Small Protein) Is in the Cytosol, It Will Also Be in the Nucleus. , 2021, Bioconjugate chemistry.

[9]  N. Heuzé-Vourc’h,et al.  Inhaled antibodies: formulations require specific development to overcome instability due to nebulization , 2021, Drug Delivery and Translational Research.

[10]  K. Nikula,et al.  BSTP Review of 12 Case Studies Discussing the Challenges, Pathology, Immunogenicity, and Mechanisms of Inhaled Biologics , 2021, Toxicologic pathology.

[11]  K. Thanki,et al.  Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF-α siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles , 2021, Frontiers in Bioengineering and Biotechnology.

[12]  M. Cazzola,et al.  Prospects for COPD treatment. , 2020, Current opinion in pharmacology.

[13]  A. Fabro,et al.  Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians , 2020, Respiratory Medicine.

[14]  D. Knoell,et al.  Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[15]  M. Huber-Lang,et al.  Inflammation, Thrombosis, and Destruction: The Three-Headed Cerberus of Trauma- and SARS-CoV-2-Induced ARDS , 2020, Frontiers in Immunology.

[16]  L. Sechi,et al.  Role of Infections in the Pathogenesis of Rheumatoid Arthritis: Focus on Mycobacteria , 2020, Microorganisms.

[17]  L. Yeo,et al.  Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study , 2020, Frontiers in Pharmacology.

[18]  K. Tremblay,et al.  Protein phosphatase 1 regulatory subunit 35 is required for ciliogenesis, notochord morphogenesis, and cell-cycle progression during murine development. , 2020, Developmental biology.

[19]  Bo Hu,et al.  Therapeutic siRNA: state of the art , 2020, Signal Transduction and Targeted Therapy.

[20]  Anders Wittrup,et al.  Imaging small molecule-induced endosomal escape of siRNA , 2020, Nature Communications.

[21]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[22]  V. Rotello,et al.  Direct Cytosolic Delivery of Proteins Through Co-Engineering of Proteins and Polymeric Delivery Vehicles. , 2020, Journal of the American Chemical Society.

[23]  K. Deane,et al.  Lung inflammation in the pathogenesis of rheumatoid arthritis , 2020, Immunological reviews.

[24]  Xin Xu,et al.  Efficient and targeted drug/siRNA co-delivery mediated by reversibly crosslinked polymersomes toward anti-inflammatory treatment of ulcerative colitis (UC) , 2019, Nano Research.

[25]  P. Baatsen,et al.  Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy. , 2018, Acta biomaterialia.

[26]  V. Rotello,et al.  Nanocapsule‐mediated cytosolic siRNA delivery for anti‐inflammatory treatment , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[27]  William J Peveler,et al.  A Rapid and Robust Diagnostic for Liver Fibrosis Using a Multichannel Polymer Sensor Array , 2018, Advanced materials.

[28]  A. Khvorova,et al.  Improving siRNA Delivery In Vivo Through Lipid Conjugation. , 2018, Nucleic acid therapeutics.

[29]  Y. Taufiq-Yap,et al.  The crucial roles of inflammatory mediators in inflammation: A review , 2018, Veterinary world.

[30]  Gregg A. Duncan,et al.  Fate of PEGylated antibody fragments following delivery to the lungs: Influence of delivery site, PEG size and lung inflammation , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[31]  A. Choi,et al.  Autophagy and inflammation in chronic respiratory disease , 2018, Autophagy.

[32]  G. Aulakh Neutrophils in the lung: “the first responders” , 2018, Cell and Tissue Research.

[33]  Danhua Zhu,et al.  Transporting carriers for intracellular targeting delivery via non-endocytic uptake pathways , 2017, Drug delivery.

[34]  Andrew J. deMello,et al.  High-Throughput Multi-parametric Imaging Flow Cytometry , 2017 .

[35]  N. Gupta,et al.  Immunological Aspect of Radiation-Induced Pneumonitis, Current Treatment Strategies, and Future Prospects , 2017, Front. Immunol..

[36]  Yi-Wei Lee,et al.  Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing. , 2017, ACS nano.

[37]  T. Mustelin,et al.  Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation , 2017, Pharmacology & therapeutics.

[38]  Kevin S. O’Fallon,et al.  Characterization of neutrophils and macrophages from ex vivo-cultured murine bone marrow for morphologic maturation and functional responses by imaging flow cytometry. , 2017, Methods.

[39]  S. Hobbs,et al.  Beyond bronchitis: a review of the congenital and acquired abnormalities of the bronchus , 2016, Insights into Imaging.

[40]  H. Derendorf,et al.  Ciclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids. , 2016, Journal of pharmaceutical sciences.

[41]  L. Kong,et al.  Therapeutic effects of histone deacetylase inhibitors in a murine asthma model , 2016, Inflammation Research.

[42]  M. Cazzola,et al.  Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease , 2016, Drugs.

[43]  S. Chaieb,et al.  Cholesterol Depletion from a Ceramide/Cholesterol Mixed Monolayer: A Brewster Angle Microscope Study , 2016, Scientific Reports.

[44]  A. Elhissi,et al.  Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications , 2016, Medical Principles and Practice.

[45]  Judy Lieberman,et al.  Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown , 2015, Nature Biotechnology.

[46]  V. Rotello,et al.  Direct cytosolic delivery of siRNA using nanoparticle-stabilized nanocapsules. , 2014, Angewandte Chemie.

[47]  P. Diot,et al.  Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[48]  N. McElvaney,et al.  Therapeutic aerosol bioengineering of siRNA for the treatment of inflammatory lung disease by TNFα gene silencing in macrophages. , 2014, Molecular pharmaceutics.

[49]  Robert Langer,et al.  Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity , 2014, Nature Communications.

[50]  A. Blumenthal,et al.  Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA , 2013, Molecular therapy. Nucleic acids.

[51]  Robert Langer,et al.  Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling , 2013, Nature Biotechnology.

[52]  S. Melgar,et al.  Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[53]  H. Magnussen,et al.  The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers , 2013, European Respiratory Journal.

[54]  S. Simões,et al.  Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. , 2012, Accounts of chemical research.

[55]  Young Jik Kwon,et al.  Efficient and targeted delivery of siRNA in vivo , 2010, The FEBS journal.

[56]  Leslie Y Yeo,et al.  Ultrasonic nebulization platforms for pulmonary drug delivery , 2010, Expert opinion on drug delivery.

[57]  Jianzhu Chen,et al.  A Novel Mechanism Is Involved in Cationic Lipid-Mediated Functional siRNA Delivery , 2009, Molecular pharmaceutics.

[58]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[59]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[60]  T. Mukherjee,et al.  Role of TNFα in pulmonary pathophysiology , 2006, Respiratory Research.